Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Angiogenesis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLXDC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLXDC1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View PLXDC1 Products |
| Gene Delivery | PLXDC1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer, sequence verified. |
View PLXDC1 Products |
| Benchmark Ab | Anti-PLXDC1 Recombinant Antibody Recombinant positive control derived from benchmark research clones. |
View PLXDC1 Products |
| Validator | PLXDC1 siRNA Set For knockdown verification in functional assays. |
View PLXDC1 Products |
| Related Target A | PLXDC2 Homologue sharing high sequence identity; essential for off-target and selectivity screening. |
View PLXDC2 Products |
| Related Target B | VEGFR2 Synergistic pathway marker in tumor angiogenesis and endothelial cell signaling. |
View VEGFR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus PLXDC1 ortholog proteins available with >95% purity |
| Subfamily counter screening (PLXDC2) | PLXDC2 homolog panel proteins strictly verified by mass spectrometry and sequence alignment |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration |
| False Positives | Validated siRNA included for target-specific knockdown verification |
Live PLXDC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PLXDC1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T cell therapies. As first-generation angiogenesis inhibitors face resistance, the next wave of R&D is targeting PLXDC1 due to its highly restricted expression on tumor endothelial cells and select solid tumor membranes, minimizing systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Biotech Innovators, Academic Consortia | Solid Tumors, Osteosarcoma | Internalization Assay (Need high-purity ECD-Fc) |
| CAR-T | Cell Therapy Specialists | Glioblastoma, Ovarian Cancer | Target Density & Specificity Validation (Need Lentivirus for Stable Cell Lines) |
| Bispecific Ab | Oncology Biopharma | Neovascularized Tumors | Dual-Target Affinity Binding (Need Cross-reactive Proteins) |